Evidence map›Paper›PMID 29161447›Full record

ArticleNucleic acids research2018

DNA polymerase beta participates in DNA End-joining.

Sreerupa Ray, Gregory Breuer, Michelle DeVeaux, Daniel Zelterman, Ranjit Bindra, Joann B Sweasy

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Engineering a Virus-Derived X Family DNA Polymerase FvPolX for de novo DNA Synthesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Article
  5. Harnessing DNA polymerase beta defect enhances synthetic lethality and treatment response in gastric cancer cells: implication for immunotherapy.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Targeting the DNA Damage Response for Cancer Therapy.International journal of molecular sciences · 2023
    Review
  11. Multifaceted Nature of DNA Polymerase θ.International journal of molecular sciences · 2023
    Review
  12. Polλ promotes microhomology-mediated end-joining.Nature structural & molecular biology · 2023
    Article
  13. Critical DNA damaging pathways in tumorigenesis.Seminars in cancer biology · 2022
    Review
  14. The Role of Protein Arginine Methyltransferases in DNA Damage Response.International journal of molecular sciences · 2022
    Review
  15. Article
  16. The Role of Natural Polymorphic Variants of DNA Polymerase β in DNA Repair.International journal of molecular sciences · 2022
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sreerupa RayDepartment of Therapeutic Radiology, School of Public Health, Yale University School of Medicine, New Haven, CT 06520-8034, USA.
Gregory BreuerDepartment of Therapeutic Radiology, School of Public Health, Yale University School of Medicine, New Haven, CT 06520-8034, USA.
Michelle DeVeauxSchool of Public Health, Yale University School of Medicine, New Haven, CT 06520-8034, USA.
Daniel ZeltermanSchool of Public Health, Yale University School of Medicine, New Haven, CT 06520-8034, USA.
Ranjit BindraDepartment of Therapeutic Radiology, School of Public Health, Yale University School of Medicine, New Haven, CT 06520-8034, USA.
Joann B SweasyDepartment of Therapeutic Radiology, School of Public Health, Yale University School of Medicine, New Haven, CT 06520-8034, USA.
Yale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007205 · NIGMS · YALE UNIVERSITY · PI KAZMIERCZAK, BARBARA I · 1985 to 2019
$42.9M
DNA Polymerase Beta Variants and CancerR01ES019179 · NIEHS · YALE UNIVERSITY · PI SWEASY, JOANN B. · 2010 to 2020
$3.9M
NCATS NIH HHS UL1 TR001863NIEHS NIH HHS R01 ES019179NIGMS NIH HHS T32 GM007205
6 · The paper itself

Abstract

DNA double strand breaks (DSBs) are one of the most deleterious lesions and if left unrepaired, they lead to cell death, genomic instability and carcinogenesis. Cells combat DSBs by two pathways: homologous recombination (HR) and non-homologous end-joining (NHEJ), wherein the two DNA ends are re-joined. Recently a back-up NHEJ pathway has been reported and is referred to as alternative NHEJ (aNHEJ), which joins ends but results in deletions and insertions. NHEJ requires processing enzymes including nucleases and polymerases, although the roles of these enzymes are poorly understood. Emerging evidence indicates that X family DNA polymerases lambda (Pol λ) and mu (Pol μ) promote DNA end-joining. Here, we show that DNA polymerase beta (Pol β), another member of the X family of DNA polymerases, plays a role in aNHEJ. In the absence of DNA Pol β, fewer small deletions are observed. In addition, depletion of Pol β results in cellular sensitivity to bleomycin and DNA protein kinase catalytic subunit inhibitors due to defective repair of DSBs. In summary, our results indicate that Pol β in functions in aNHEJ and provide mechanistic insight into its role in this process.

Indexed as

DNA Breaks, Double-StrandedDNA End-Joining RepairCell Line, TumorDNADNA-Binding ProteinsDNA DamageDNA Polymerase betaDNA ReplicationHumansMCF-7 CellsDNADNA-Binding ProteinsDNA Polymerase beta

Identifiers

PMID29161447
PMCPMC5758893
OpenAlexW2771003110

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.